The company announced significant advancements in its precision diagnostics platform, including an upgraded multi-modal Signatera MRD model for oncology and expanded AI collaborations with NVIDIA to train models for faster data analysis. New clinical data in colorectal cancer and validation for its fetal genetic test were also reported. These developments leverage one of the world's largest longitudinal oncology datasets to strengthen its position in the growing genomic testing market, which is projected to expand significantly by 2035.